| tyyppi | julkaisu |
| 3 | Lehti | Trissel LA, Martinez JF.Compatibility of amifostine with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 36 | Lehti | Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.Am J Health-Syst Pharm 1995 ; 52: 2423-2426. |
| 58 | Lehti | Parker WA.Physical compatibility of ranitidine HCl with preoperative injectable medications.Can J Hosp Pharm 1985 ; 38: 160-161. |
| 59 | Lehti | Trissel LA, Gilbert DL, Martinez JF, Kim MC.Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 62 | Lehti | Pugh CB, Pabis DJ, Rodriguez C.Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.Am J Hosp Pharm 1991 ; 48: 123-125. |
| 73 | Lehti | Lor E, Takagi J.Visual compatibility of foscarnet with other injectable drugs.Am J Hosp Pharm 1990 ; 47: 157-159. |
| 81 | Lehti | Trissel LA, Martinez JF.Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 | Lehti | Trissel LA, Martinez JF.Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.Am J Hosp Pharm 1994 ; 51: 495-499. |
| 85 | Lehti | Trissel LA, Bready BB.Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.Am J Hosp Pharm 1992 ; 49: 1716-1719. |
| 91 | Lehti | Lober CA, Dollard PA.Visual compatibility of gallium nitrate with selected drugs during Y-site injection.Am J Hosp Pharm 1993 ; 50: 1208-1210. |
| 99 | Lehti | Trissel LA, Martinez JF.Compatibility of aztreonam with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 153 | Lehti | Wang DP, Chang LC, Lee DK.Stability of fluorouracil-metoclopramide hydrochloride admixture.Am J Health-Syst Pharm 1995 ; 52: 98-99. |
| 169 | Lehti | Trissel LA, Martinez JF.Physical compatibility of melphalan with selected drugs during simulated Y-site administration.Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 180 | Lehti | Zhang Y, Trissel LA, Martinez JF, Gilbert DL.Stability of metoclopramide hydrochloride in plastic syringes.Am J Health-Syst Pharm 1996 ; 53: 1300-1302. |
| 182 | Lehti | Trissel LA, Gilbert DL, Martinez JF.Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 198 | Lehti | Gayed AA, Kheshary PR, Hinkle RL.Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 215 | Lehti | Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 244 | Lehti | Trissel LA, Martinez JF.Compatibility of filgrastim with selected drugs during simulated Y-site administration.Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 | Lehti | Trissel LA, Martinez JF.Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 | Lehti | Trissel LA, Gilbert DL, Martinez JF.Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 253 | Lehti | Trissel LA, Chandler SW, Folstad JT.Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.Am J Hosp Pharm 1990 ; 47: 2525-2528. |
| 266 | Lehti | Patel PR.Compatibility of meropenem with commonly used injectable drugs.Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
| 288 | Lehti | Cervenka P, Dejong DJ, Butler BL, Monzingo MD.Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.Hosp Pharm 1992 ; 27: 957-958,961-962. |
| 289 | Lehti | Jim LK.Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.Ann Pharmacotherapy 1993 ; 27: 704-707. |
| 299 | Lehti | Trissel LA, Martinez JF, Gilbert DL.Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 | Lehti | Trissel LA, Gilbert DL, Martinez JF.Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 | Lehti | Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 | Lehti | Trissel LA, Martinez JF.Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 334 | Lehti | Trissel LA, Tramonte SM, Grilley BJ.Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.Am J Hosp Pharm 1991 ; 48: 988-992. |
| 335 | Lehti | Trissel LA, Bready BB, Kwan JW, Santiago NM.Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.Am J Hosp Pharm 1992 ; 49: 402-406. |
| 336 | Lehti | Forman JK, Lachs JR, Souney PF.Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.Am J Hosp Pharm 1987 ; 44: 1408-1409. |
| 337 | Lehti | Bashaw ED, Amantea MA, Minor JR, Galleli JF.Visual compatibility of zidovudine with other drugs during simulated Y-site administration.Am J Hosp Pharm 1988 ; 45: 2532-2533. |
| 397 | Lehti | Fong PA, Ward J.Visual compatibility of intravenous famotidine with selected drugs.Am J Hosp Pharm 1989 ; 46: 125-126. |
| 404 | Lehti | Forman JK, Souney PF.Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.Am J Hosp Pharm 1987 ; 44: 2298-2299. |
| 479 | Lehti | Min DI, Brown T, HWang GC.Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 491 | Lehti | Turowski RC, Durthaler JM.Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.Am J Hosp Pharm 1991 ; 48: 2181-2184. |
| 492 | Lehti | Trissel LA, Parks NPT, Santiago NM.Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 | Lehti | Lor E, Sheybani T, Takagi J.Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.Am J Hosp Pharm 1991 ; 48: 744-746. |
| 519 | Lehti | Poggi GL.Compatibility of morphine tartrate admixtures in polypropylene syringes.Aust J Hosp Pharm 1991 ; 21: 316. |
| 660 | Lehti | Michaels MR, Stauffer GL, Haas DP.Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 763 | Lehti | Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.Cancer Treat Rep 1985 ; 69: 1325-1326. |
| 815 | Lehti | Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL.Stability of ondansetron hydrochloride and 12 medications in plastic syringes.Am J Health-Syst Pharm 1998 ; 55: 2630-2634. |
| 905 | Lehti | Trissel LA, Martinez JF.Screening teniposide for Y-site physical incompatibilities.Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 | Lehti | Trissel LA, Gilbert DL, Martinez JF.Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.Hosp Pharm 1998 ; 33: 284-292. |
| 930 | Lehti | Hor MMS, Chan SY, Yow KL, Lim LY, Chan E.Stability of admixtures of pethidine and metoclopramide in aqueous solution, 5% dextrose and 0.9% sodium chloride.J Clin Pharm Ther 1997 ; 22: 339-345. |
| 1026 | Lehti | Mayron D, Gennaro AR.Stability and compatibility of topotecan hydrochloride with selected drugs.Am J Health-Syst Pharm 1999 ; 56: 875-881. |
| 1057 | Lehti | Cutie MR.Compatibility of verapamil hydrochloride injection with commonly used additives.Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1072 | Lehti | Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.Compatibility of levofloxacin with 34 medications during simulated Y-site administration.Am J Health-Syst Pharm 1999 ; 56: 1458-1459. |
| 1135 | Lehti | Baltz JK, Kennedy P, Minor JR, Gallelli J.Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.Am J Hosp Pharm 1990 ; 47: 2075-2077. |
| 1230 | Lehti | Regnard C, Pashley S, Westrope F.Anti-emetic / diamorphine mixture compatibility in infusion pumps.Br J Pharm Pract 1986 ; 8: 218-220. |
| 1232 | Lehti | Beatson C, Taylor A.A physical compatibility study of furosemide & flucloxacillin injections.Br J Pharm Pract 1987 ; 9: 223-226, 236. |
| 1405 | Lehti | Peterson GM, Miller KA, Galloway JG, Dunne PF.Compatibility and stability of fentanyl admixtures in polypropylene syringes.J Clin Pharm Ther 1998 ; 23: 67-72. |
| 1410 | Lehti | Trissel LA, Martinez JF, Simmons M.Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 | Lehti | Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.Compatibility of medications with 3-in-1 parenteral nutrition admixtures.JPEN 1999 ; 23: 67-74. |
| 1423 | Lehti | Trissel LA, Martinez JF, Gilbert DL.Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1455 | Lehti | Demoré B, Raffy F, Commun N, Vigneron J, Hoffman MA, Hoffman M.Etude de la stabilité de deux benzamides antiémétiques en poches PVC de chlorure de sodium 0.9% et de glucose 5% sur une période de 5 mois.J Pharm Clin 1995 ; 14: 178-179. |
| 1495 | Lehti | Nixon AR, O'Hare MCB, Chisakuta AM.The stability of morphine sulphate and metoclopramide hydrochloride in various delivery presentations.Pharm J 1995 ; 254: 153-155. |
| 1496 | Lehti | Trissel LA, Martinez JF, Gilbert DL.Screening cladribine for Y-site physical compatibility with selected drugs.Hosp Pharm 1996 ; 31: 1425-1428. |
| 1513 | Laboratorio | Quinupristine / dalfopristine (Synercid®) - Résumé des caractéristiques du produitMonarch Pharmaceuticals Ireland 2006 |
| 1625 | Lehti | Trissel LA, Saenz C, Williams YW, Ingram D.Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.Int J Pharm Compound 2001 ; 5: 314-321. |
| 1662 | Lehti | Trissel LA, Saenz CA, Ingram DS, Ogundele AB.Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1712 | Lehti | Trissel LA, Saenz CA.Compatibility screening of Precedex during simulated Y-site administration with other drugs.Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 | Lehti | Trissel LA, Saenz CA.Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 | Lehti | Trissel LA, Williams KY, Baker MB.Compatibility screening of Hextend during simulated Y-site administration with other drugs.Int J Pharm Compound 2001 ; 5: 69-72. |
| 1754 | Lehti | Trissel LA, Gilbert DL, Wolkin AC.Compatibility of docetaxel with selected drugs during simulated Y-site administration.Int J Pharm Compound 1999 ; 3: 241-244. |
| 1757 | Lehti | Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P.Determination of compatibility and stability of drugs used in palliative care.J Clin Pharm Ther 1998 ; 23: 311-314. |
| 1802 | Lehti | Bell MS, Nolt DH.Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.Am J Health-Syst Pharm 2003 ; 60: 193-194. |
| 1803 | Lehti | Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1847 | Lehti | Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G.Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration.J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241. |
| 1925 | Lehti | Trissel LA , Williams KY, Gilbert DL.Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1953 | Lehti | Trissel LA, Saenz CA, Ogundele AB, Ingram DS.Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1957 | Lehti | Gupta VD.Chemical stability of metoclopramide hydrochloride injection diluted with 0.9% sodium chloride injection in polypropylene syringes at room temperature.Int J Pharm Compound 2005 ; 9, 1: 72-74. |
| 1971 | Lehti | Azuara ML, Sanchez Y, Reyes R, Barcia E.Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care.Support Care Cancer 2001 |
| 1974 | Lehti | Chandler SW, Trissel LA, Weinstein SMCombined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.J Pain Symptom Manage 1996 ; 12, 3: 168-171. |
| 2090 | Lehti | Pere H, Chasse V, Forest JM, Hildgen P.Compatibility of injectable pantoprazole in Y-site administration.Pharmactuel 2004 ; 37: 193-196. |
| 2109 | Lehti | Pelletier E, Forest JM, Hildgen P.Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.Pharmactuel 2006 ; 39: 71-75. |
| 2125 | Lehti | Gardiner PR.Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration.Hospital Pharmacist 2003 ; 10: 354-361. |
| 2166 | Lehti | Nassr S, Dubuc MC, Lavoie P, Brazier JL.HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine.J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929. |
| 2179 | Lehti | Trusley C, Ben M, Kupiec TC, Trissel LA.Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration.Int J Pharm Compound 2007 ; 11, 1: 82-85. |
| 2262 | Lehti | Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.Compatibility of doripenem with other drugs during simulated Y-site administratioNAm J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 2269 | Lehti | Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 2335 | Lehti | Canann D, Tyler L.S, Barker B, Condie C.Visual compatibility of i.v. medications routinely used in bone marrow transplant recipientsAm J Health-Syst Pharm 2009 ; 66, 8: 727-729 |
| 2900 | Lehti | Hines S, Pleasance S.Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration.EJHP 2009 ; 15, 5: 32-38. |
| 3012 | Lehti | Sullivan T, Forrest J.M, Leclair G.Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3082 | Lehti | Athanasopoulos A, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L.Long-term stability of tramadol chlorhydrate and metoclopramide hydrochloride in dextrose 5% polyolefin bag at 4°C.J Oncol Pharm Practice 2009 ; 15: 195-200. |
| 3184 | Laboratorio | Hyaluronidase (Hyalase®) - Summary of Product characteristics.CP Pharmaceuticals 2005 |
| 3216 | Lehti | Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 | Lehti | Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3254 | Lehti | Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3332 | Laboratorio | Tigecycline (Tigacyl®) - Summary of Product characteristicsPfizer 2012 |
| 3372 | Lehti | Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.Rev Bras Anestesiol 2013 ; 63, 1: 163-166. |
| 3379 | Lehti | Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.Am J Health-Syst Pharm 2013 ;70:520-524. |
| 3408 | Lehti | Tollec S, Touzin K, Pelletier E, Forest J.M.Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3474 | Laboratorio | Fluorouracil - Summary of Product CharacteristicsAccord Healthcare Limited 2009 |
| 3558 | Lehti | Rowe H, Riley J, Newby B.Physical Compatibility of Ranitidine and Metoclopramide in 50-mL Minibags of Normal Saline.Can J Hosp Pharm 2013 ; 66, 5: 332. |
| 3637 | Laboratorio | Methotrexate (Methotrexate solution for injection®) - Summary of Product CharacteristicsHameln Pharmaceuticals 2014 |
| 3767 | Lehti | Legris M.E, Lavoie A, Forrest J.M, Hildgen P.Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3779 | Lehti | Kintzel P.E, Zhao T, Wen B, Sun D.Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection Am J Health-Syst Pharm 2014 ; 71:2061-2065 |
| 3791 | ilmoitus | Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.Apifh Congress, Paris November 2014 2014 |
| 3824 | Lehti | Boudi S, Roy H, Forest JM, Leclair G.Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.Pharmactuel 2023 2023;56,3:91-98 |
| 3827 | ilmoitus | Ghazi I.M, Hamada Y, Nicolau D.P.Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.ASHP Midyear 2015 |
| 3828 | ilmoitus | Thabit A.K, Hamada Y, Nicolau D.P.Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.ASHP Midyear 2015 |
| 3829 | ilmoitus | So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.Compatibility of isavunazonium sulfate during simulated Y-site administration.ASHP Midyear 2015 |
| 3948 | Lehti | Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.JPEN 2012 ;30. 416?424. |
| 3964 | Lehti | Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.Pharmactuel 2017 ; 50,1 : 27-33. |
| 4055 | Lehti | Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4145 | Lehti | Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4319 | Lehti | Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4404 | ilmoitus | Müller U, Haller F, Wiedemeier P, Steuer C.Compatibility studies of seven commonly used drugs for parenteral administration in palliative care.JFSPH 2019 2019 |
| 4433 | Lehti | Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous MedicationsClin Ther 2020 ; 42, 3: 475-485. |
| 4521 | Lehti | Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.Pharmaceutical Technology in Hospital Pharmacy 2020 |
| 4528 | Lehti | Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.Int J Pharm Compound 2021 ;25,1:52-61 |
| 4603 | Lehti | Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4642 | ilmoitus | Larossa garcia M, Jimenez-Lozano I, Boix-Montanés A, Mallandrich Miret M, Clemente Bautista M, cabanas Poy M.J., Gorgas Torner Compatibilidad en Y de atosiban y farmacois habitualmente utilizados en obstetricia.SEFH Congress (Virtual) October 2021 2021 |
| 4650 | Laboratorio | Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.Advanz Pharma 2021 |
| 4742 | Lehti | Macoviciuc M, Nguyen C, Forest J-M, Leclair G.Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.Pharmactuel 2022 ; 55, 4: 247-255. |
| 4801 | Lehti | Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.Am J Health-Syst Pharm 2024 ;51,1: |
Viimeisin päivitys :19/11/2024 
Infostab 
Luettelo yhdisteistä 
Yhteenveto-luettelot 
Etsi yhteensopivuutta 
Y-sivuston yhteensopivuustaulukko 
Viitteet 
tutkimus Joukkueet 
valistab 
ilmoitus 
Liitännät 
sponsorit 
Tekijät 
Käyttöohje 
Uutiskirje 
